心理治疗与药物治疗对成人精神障碍的疗效:对近期Meta分析的伞状综述与Meta分析评价
该伞状综述纳入102项Meta分析(含3782项随机对照试验、650514例患者),覆盖抑郁、焦虑、创伤后应激障碍、强迫症、躯体形式障碍、进食障碍、注意缺陷/多动障碍、物质使用障碍、失眠、精神分裂症谱系障碍和双相障碍。与安慰剂或常规治疗相比,心理治疗和药物治疗的标准化均数差分别为0.34(95%CI 0.26-0.42)和0.36(95%CI 0.32-0.41),多数效应量较小。
要点
- 心理治疗与药物治疗的效应量多数较小,SMD分别为0.34和0.36。
- 心理治疗与药物治疗头对头比较SMD为0.11(95%CI -0.05至0.26)。
- 联合治疗优于单药治疗,SMD为0.31(95%CI 0.19-0.44)。
核心结论
- 经过半个多世纪研究、数千项随机对照试验和大量资金投入,心理治疗和药物治疗对精神障碍的效应量有限,提示当前治疗研究存在天花板效应;实现进一步进展似乎需要研究范式的转变。
研究设计与样本
- 伞状综述,检索PubMed和PsycINFO及Cochrane Library个体记录,纳入2014年1月至2021年3月发表的Meta分析,共102项Meta分析、3782项随机对照试验、650514例患者。
主要发现
- 与安慰剂或常规治疗相比,心理治疗的SMD为0.34(95%CI 0.26-0.42),药物治疗的SMD为0.36(95%CI 0.32-0.41)。
- 心理治疗与药物治疗头对头比较的SMD为0.11(95%CI -0.05至0.26)。
- 联合治疗与任一单药治疗相比的SMD为0.31(95%CI 0.19-0.44)。
- 偏倚风险常常较高。
关键数值与推荐
- 纳入的Meta分析正式评估了偏倚风险或研究质量,排除了弱对照,并以目标症状的效应量作为主要结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mental disorders represent a worldwide public health concern. Psychotherapies and pharmacotherapies are recommended as first line treatments. However, evidence has emerged that their efficacy may be overestimated, due to a variety of shortcomings in clinical trials (e.g., publication bias, weak control conditions such as waiting list). We performed an umbrella review of recent meta-analyses of randomized controlled trials (RCTs) of psychotherapies and pharmacotherapies for the main mental disorders in adults. We selected meta-analyses that formally assessed risk of bias or quality of studies, excluded weak comparators, and used effect sizes for target symptoms as primary outcome. We searched PubMed and PsycINFO and individual records of the Cochrane Library for meta-analyses published between January 2014 and March 2021 comparing psychotherapies or pharmacotherapies with placebo or treatment-as-usual (TAU), or psychotherapies vs. pharmacotherapies head-to-head, or the combination of psychotherapy with pharmacotherapy to either monotherapy. One hundred and two meta-analyses, encompassing 3,782 RCTs and 650,514 patients, were included, covering depressive disorders, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, somatoform disorders, eating disorders, attention-deficit/hyperactivity disorder, substance use disorders, insomnia, schizophrenia spectrum disorders, and bipolar disorder. Across disorders and treatments, the majority of effect sizes for target symptoms were small. A random effect meta-analytic evaluation of the effect sizes reported by the largest meta-analyses per disorder yielded a standardized mean difference (SMD) of 0.34 (95% CI: 0.26-0.42) for psychotherapies and 0.36 (95% CI: 0.32-0.41) for pharmacotherapies compared with placebo or TAU. The SMD for head-to-head comparisons of psychotherapies vs. pharmacotherapies was 0.11 (95% CI: -0.05 to 0.26). The SMD for the combined treatment compared with either monotherapy was 0.31 (95% CI: 0.19-0.44). Risk of bias was often high. After more than half a century of research, thousands of RCTs and millions of invested funds, the effect sizes of psychotherapies and pharmacotherapies for mental disorders are limited, suggesting a ceiling effect for treatment research as presently conducted. A paradigm shift in research seems to be required to achieve further progress.
引用
- Leichsenring F, Steinert C, Rabung S, et al. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry. 2022. PMID: 35015359. doi:10.1002/wps.20941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。